Millipore has made available Protein Blotting Sandwiches that offer
convenience and time savings for high throughput labs using
chemiluminescent or chromogenic detection methods.
BASF is targeting the pharma industry at ChemSpec this June with
new intermediates, catalysts and raw materials that promise to make
customers' syntheses less complex and time-consuming as well as
more cost-effective.
UK-based Malvern Instruments has been busy streamlining its
particle characterisation contract testing services at its global
locations, with the latest reshuffle taking place in France.
MFIC Corporation, whose Microfluidics Division manufactures
industrial submicron processing equipment, has returned to
profitability in the first quarter of 2006 after big losses in
first quarter of last year, buoyed by increased...
IT services company HCL Technologies continues to experience rapid
growth through its ability to undercut clinical research
organisations (CROs) on price for clinical data management (CDM)
services through its new operations in India.
The Tampa-based formulation development laboratory of MDS Pharma
Services has split from its parent company and formed a new firm
with the technology to get active pharmaceutical ingredients (APIs)
directly into capsules.
India's Dishman Pharmaceuticals & Chemicals has snapped up the
Swiss-based pharmaceutical services business, Carbogen and Amcis,
of financially-troubled US chemical firm Solutia for the sum of
$74.5m (€58m).
Microbia has presented clinical data that shows its first-in-class
drug for the treatment of constipation-predominant irritable bowel
syndrome (IBS-C) and chronic constipation (CC), demonstrated
promising pharmacodynamic effects.
A new drug discovery approach, which essentially reverses the
process of drug compound screening promises a increased efficiency
in drug discovery whilst keeping costs down to a minimum.
According to a new report, the European central nervous system
therapeutic market is set to capitalise on an ageing population, a
high level of unmet clinical need and increasing prevalence of
neurological disorders, growing to $31.31bn...
Cisbio has introduced its second IP-One assay, which can be used by
all laboratories focused on GPCR-based targets of which 45 per cent
of currently marketed drugs owe their efficacy to.
Accium BioSciences and Quintiles Transnational has established an
agreement, which intends to offer turnkey Exploratory-IND,
Microdosing and Information-Rich Phase I clinical trials services
to biopharmaceutical researchers.
Registration is now open for the annual "Pharmaceutical Outsourcing
of Discovery Chemistry, Advanced Intermediates and API's"
conference, which this year celebrates its 10th anniversary.
US biotech company Spherix has selected Singapore-based clinical
research organisation (CRO) Gleneagles to take charge of the Phase
III clinical trial program for its new Type 2 diabetes drug,
Naturlose.
Bioprogress has signed a development agreement with emerging
speciality pharmaceutical company Uluru to combine their film
technologies in order to create an edible film which allows
sustained release of active ingredients.
Matritech has introduced the first urine test that indicates
whether a bladder malignancy is likely to be dangerous, providing
early identification of high-risk tumours and therefore increasing
the success of subsequent treatment.
Biophan has filed the first patent to come out of its newly-formed
relationship with NaturalNano to develop new and improved ways of
controlled-release drug delivery.
Life sciences firm Cambrex has agreed a contract for the production
of clinical trial quantities of Merrimack Pharmaceuticals'
recombinant immunomodulatory serum protein, as its experience in
the downstream purification of proteins...
India's Ranbaxy Laboratories has stepped up its efforts to dominate
the domestic novel drug delivery system (NDDS) market, in-licensing
two new drugs from Europe in as many weeks.
The World Health Organization (WHO) has announced details of a new
initiative compelling drug companies to register all clinical
trials on humans after public pressure for more transparency.
Amcor Flexibles has launched a new tear open feature for foil drug
packaging that it claims is both child resistant and senior
friendly and cheaper to make than current methods.
The European Medicines Agency (EMEA) has given Sanofi Pasteur the
green light to market a childhood vaccine containing Delta's
Recombumin, a recombinant human albumin which offers the world's
first and only animal-free alternative...
French separations specialist Novasep has launched two new
chromatography systems, promising new levels of efficency in
preparative high performance liquid chromatography (HPLC).
A new polymer drug delivery technology developed by Dutch firm
OctoPlus has cleared Phase I trials for the first time, showing
promise in a new controlled release treatment of chronic hepatitis
C.
Abraxis Bioscience has added a research facility to expand the
company's research and process development capabilities that use
the company's nab technology platform, which identifies new
chemical entities and exploitation...
General Electric and MDS Pharma Services announced today the
availability of a new, automated in vitro micronucleus assay that
will form part of a broad panel of drug discovery safety
assessments offered by MDS Pharma Services pharmacology...
Specialty chemicals group H&R Wasag witnessed tremendous growth
in the first quarter of 2006, as stable crude oil prices allowed it
to increase prices and volumes in the pharmaceutical raw materials
it sells.
Cambridge Antibody Technology (CAT) posted a first-half profit for
the year that was attributed to royalty payments for its Humira
rheumatoid arthritis drug.
Contract biomanufacturing firm Laureate has won a contract to
produce Seattle Genetics' humanised monoclonal antibody product
candidates for clinical trial, adding to its experience in
monoclonal antibody development.
Lonza has been authorised by the US Food and Drug Administration
(FDA) to produce Bristol-Myers Squibb's arthritis drug Orencia
(abatacept), in what is shaping up to be a major manufacturing deal
for the Swiss company.
German biopharmaceutical company Boehringer Ingelheim has clinched
a licencing deal for XstalBio's formulation and stabilisation
technology which can be applied to the delivery of biomolecules via
a number of routes, including...
Private US biosciences company Codexis has acquired the assets of
private Dutch company Enzis. Included in the deal are the patents
to several new classes of enzymes that Codexis will use to develop
cheaper and faster drug manufacturing...
The boom in advanced drug delivery devices is creating demand for
specialist manufacturers that can rise to the challenge of making
these complicated devices, although such companies are currently
thin on the ground.
Vandalia Research has launched a new DNA amplification service that
it claims will speed up the mass production of high-quality DNA
sequences with the polymerase chain reaction (PCR), while at the
same time reducing the risk of contamination.
The laboratory identification of promising candidates for new
anti-cancer drugs is to be made significantly easier after
scientists developed a litmus test that determines the bonding
strength of DNA, small molecules and proteins...
Kendle has seized a chance to expand and diversify its business,
snapping up the Phase II-IV Clinical Services unit of Charles River
Laboratories after it decided to get out of this area of clinical
trial services and focus instead...
Skyepharma has finally found a partner to license and market its
new asthma drug delivery product after over a year of searching and
one big-pharma partnership that went belly up in 2005 - giving the
company new hope of revamping...
Biophage has completed the final phase of its CRO business
restructuring in preparation to meet the expected demand in
immunotoxicity testing, in which its requirement stems from
increasing legislation that calls for stricter standards.
A new drug discovery technique, which uses mixed-mode sorbents in
process chromatography, has the potential to significantly reduce
costs and environmental burdens, especially in the protein
purification process.
US scientists have uncovered a mechanism of action that explains
how cells respond to DNA damage and other stresses that if
disrupted can cause cancer. The discovery could lead to new
diagnostic markers and cancer treatments with...
Pfizer has sold a large manufacturing plant in Puerto Rico to
biopharmaceutical firm Abraxis for $32.5m (€25.4m), as it continues
to consolidate its manufacturing operations.
As it prepares for the launch of GlaxoSmithKline's beta-blocker
Coreg (carvedilol) with a controlled release formulation, drug
delivery company Flamel saw its bottom line, in the absence of new
partners, shift deep into the red...
Global packaging giant MeadWestvaco has acquired Saint-Gobain
Calmar, a manufacturer of plastic dispensing and spraying systems,
looking to establish a solid footing in primary packaging.
A team of drug researchers are exploring the possibility of
extracting chemical compounds from marine organisms that live in
deep-sea reefs, which have the potential to treat human diseases
such as cancer and Alzheimer's.
The World Health Organisation is calling for greater transparency
in clinical trials by announcing new registration standards for all
medical research involving humans.
Biopharmaceutical firm Oragenics has received funding from a US
government agency for a technology which promises cost-effective
production of commercially important bioactive peptides with
unusual structures.
A potential therapy, which specifically targets cancer cells, could
be in the offering after Neotropix received FDA approval to begin
clinical trials of a drug candidate that offers new drug treatment
hope for advanced cancers.
Software provider Pharsight, has been awarded a patent on its
graphical method for creating drug models, in a technique that
supports more intuitive PK/PD modelling and higher modelling
productivity.
Oxford University has made another trip to the High Court with the
intention of further limiting the number of animal rights protests,
which the institution claim is responsible for an increase in
criminal damage and staff intimidation.